https://mindmedicinelaw.com/briefing/post-trial-psilocybin-access-legal-reflections-in-the-uk-20260605-10197The Psychedelic Journalen2026-06-05T15:05:11.837310+00:00Post-Trial Psilocybin Access: Legal Reflections in the UKpsilocybin, post-trial access, UK legal case, psychedelic research, clinical trials, Schedule 1 drugs, patient access, regulatory frameworks, mental health treatment, legal complexitieshttps://mindmedicinelaw.com/briefing/ai-chatbots-and-substance-induced-psychosis-clinical-concerns-20260604-10083The Psychedelic Journalen2026-06-05T15:05:29.597502+00:00AI Chatbots and Substance-Induced Psychosis: Clinical ConcernsAI chatbots, substance-induced psychosis, mental health, clinical implications, ethical concerns, harm minimizationhttps://mindmedicinelaw.com/briefing/mdma-booster-dose-study-implications-for-clinical-trials-20260604-10103The Psychedelic Journalen2026-06-05T15:05:22.021857+00:00MDMA Booster Dose Study: Implications for Clinical TrialsMDMA booster dose, psychedelic therapy, PTSD treatment, clinical trials, subjective effects, adverse effects, dosing protocols, psychiatric disorders, MDMA-assisted therapy, neuroscience researchhttps://mindmedicinelaw.com/briefing/connecticut-expands-psychedelics-program-ahead-of-fda-approval-20260604-10195The Psychedelic Journalen2026-06-05T15:05:00.074307+00:00Connecticut Expands Psychedelics Program Ahead of FDA Approvalconnecticut psychedelics program, FDA approval, psychedelic therapy, state-level policy, clinical trials, psychedelics legal landscapehttps://mindmedicinelaw.com/briefing/ketamine-therapy-gains-traction-in-las-vegas-clinic-20260604-10037The Psychedelic Journalen2026-06-04T22:04:17.711278+00:00Ketamine Therapy Gains Traction in Las Vegas Clinicketamine therapy, mental health, psychedelic treatments, Las Vegas clinic, alternative therapies, clinical research, policy implications, treatment risks, healthcare integration, patient outcomeshttps://mindmedicinelaw.com/briefing/ketamine-oxytocin-nasal-spray-a-new-frontier-in-la-20260604-10036The Psychedelic Journalen2026-06-04T22:04:10.874021+00:00Ketamine-Oxytocin Nasal Spray: A New Frontier in LAketamine, oxytocin, nasal spray, treatment-resistant depression, PTSD, compounded formulations, mental health treatment, clinical trials, regulatory scrutiny, psychedelic therapieshttps://mindmedicinelaw.com/briefing/hnk-s-antidepressant-mechanism-opioid-receptor-heterodimerization-20260603-10133The Psychedelic Journalen2026-06-05T15:05:50.180478+00:00HNK's Antidepressant Mechanism: Opioid Receptor HeterodimerizationHNK, opioid receptor heterodimerization, antidepressant mechanism, ketamine metabolite, astrocytic receptors, rapid-acting antidepressants, mental health treatment, neuroscience, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/shared-molecular-pathways-in-mood-disorders-new-insights-20260603-10134The Psychedelic Journalen2026-06-05T15:05:39.767004+00:00Shared Molecular Pathways in Mood Disorders: New Insightsmood disorders, human habenula, transcriptomic profiling, major depressive disorder, bipolar disorder, sex-informed research, neurobiology, therapeutic strategies, gene expression, psychiatric researchhttps://mindmedicinelaw.com/briefing/integrated-treatment-model-for-opioid-use-schizophrenia-20260603-9788The Psychedelic Journalen2026-06-04T15:05:20.414039+00:00Integrated Treatment Model for Opioid Use & Schizophreniaintegrated treatment model, opioid use disorder, schizophrenia spectrum disorders, dual-diagnosis, clinical outcomes, medication adherence, emergency department visits, healthcare policy, patient engagement, mental healthhttps://mindmedicinelaw.com/briefing/iboga-microdosing-in-tbi-recovery-emerging-evidence-20260603-9801The Psychedelic Journalen2026-06-04T15:04:50.100218+00:00Iboga Microdosing in TBI Recovery: Emerging Evidenceiboga microdosing, traumatic brain injury, hypoxic brain injury, psychedelic therapy, clinical trials, neurological recovery, AEDP, ibogaine, psychedelic research, neurorehabilitationhttps://mindmedicinelaw.com/briefing/placebo-effects-in-psychedelic-research-implications-for-trials-20260602-9769The Psychedelic Journalen2026-06-04T15:05:07.938325+00:00Placebo Effects in Psychedelic Research: Implications for Trialsplacebo effects, psychedelic research, clinical trials, contextual influence, altered states of consciousness, ego dissolution, nocebo effects, set and setting, trait responsiveness, therapeutic applicationshttps://mindmedicinelaw.com/briefing/european-consensus-on-trlld-framework-for-future-research-20260602-9813The Psychedelic Journalen2026-06-04T15:04:58.979987+00:00European Consensus on TRLLD: Framework for Future Researchtreatment-resistant late-life depression, TRLLD, European task force, Delphi process, depression in elderly, clinical guidelines, operational staging model, decision-making algorithm, psychiatric research, mental health policyhttps://mindmedicinelaw.com/briefing/esketamine-and-psychotherapy-promising-combo-for-trd-20260602-9812The Psychedelic Journalen2026-06-04T15:04:27.391611+00:00Esketamine and Psychotherapy: Promising Combo for TRDesketamine, psychotherapy, treatment-resistant depression, ketamine-assisted psychotherapy, clinical trial, mental health treatment, neuroplasticity, pharmacological effects, emotional processing, integrated treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-potential-in-treating-chemobrain-a-preclinical-study-20260601-9814The Psychedelic Journalen2026-06-04T22:04:24.131366+00:00Ketamine's Potential in Treating Chemobrain: A Preclinical Studyketamine, chemobrain, depression, neuroinflammation, cancer treatment, preclinical study, signaling pathways, BDNF/TrkB, GLT-1, SERThttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-reducing-postoperative-anxiety-in-adolescents-20260601-9818The Psychedelic Journalen2026-06-04T15:04:39.998171+00:00Esketamine's Role in Reducing Postoperative Anxiety in Adolescentsesketamine, postoperative anxiety, adolescents, randomized controlled trial, perioperative care, psychological distresshttps://mindmedicinelaw.com/briefing/bdnf-as-a-biomarker-in-depression-treatment-20260601-9497The Psychedelic Journalen2026-06-03T22:04:08.593148+00:00BDNF as a Biomarker in Depression Treatmentbdnf, depression, biomarker, personalized medicine, neuroplasticity, mental health, genetic polymorphisms, epigenetic changes, treatment response, neurotrophic factorhttps://mindmedicinelaw.com/briefing/ketamine-in-hip-arthroplasty-clinical-review-insights-20260601-9538The Psychedelic Journalen2026-06-03T22:03:55.144702+00:00Ketamine in Hip Arthroplasty: Clinical Review Insightsketamine, hip arthroplasty, systematic review, pain management, clinical guidelines, anesthetic, analgesic, surgical settings, NMDA receptor, opioid consumptionhttps://mindmedicinelaw.com/briefing/us-psychedelic-facilitation-training-current-analysis-and-implications-20260529-9557The Psychedelic Journalen2026-06-03T22:04:18.892230+00:00US Psychedelic Facilitation Training: Current Analysis and Implicationspsychedelic facilitation, training programs, US policy, clinical practice, public health, psychedelic therapy, facilitator accreditation, therapeutic outcomes, risk management, psychedelic researchhttps://mindmedicinelaw.com/briefing/vagal-afferents-in-epilepsy-mechanisms-and-implications-20260525-7904The Psychedelic Journalen2026-06-03T22:04:36.567305+00:00Vagal Afferents in Epilepsy: Mechanisms and Implicationsvagal nerve stimulation, epilepsy treatment, neuroscience, clinical trials, vagal afferents, neuromodulation, temporal lobe epilepsy, VGluT2-positive afferentshttps://mindmedicinelaw.com/briefing/psilocybin-s-effects-on-planarian-behavior-insights-for-human-trials-20260525-8581The Psychedelic Journalen2026-06-03T22:04:29.153626+00:00Psilocybin's Effects on Planarian Behavior: Insights for Human Trialspsilocybin, planarian behavior, serotonin pathways, neuropharmacology, clinical trials, psychiatric disorders, therapeutic applications, psychedelic research, human trials, neurosciencehttps://mindmedicinelaw.com/briefing/swiss-survey-reveals-psychedelic-therapy-methods-20260520-8117The Psychedelic Journalen2026-06-03T22:04:44.548726+00:00Swiss Survey Reveals Psychedelic Therapy Methodspsychedelic therapy, Swiss physicians, clinical methods, standardized protocols, patient safety, international guidelines, training programs, treatment efficacy, policy implications, research directions